13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001637359
Total reported value
$185.7M
$185.7M
10 檔
78.2%
As reported in its official Q1 2026 Form 13F filing, Omega Fund Management, LLC's tracked investment portfolio stood at $185.7M with 10 total positions.
In Q1 2026, Omega Fund Management, LLC adopted a defensive or profit-taking posture, trimming 2 positions and completely liquidating 1 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics Inc | Stock-Other | 29.16% | -0.02% | +8.50% | |
| 2 | NUVB | Nuvation Bio Inc | Stock-Other | 21.25% | +3.47% | — | |
| 3 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 18.05% | -4.55% | — | |
| 4 | KMTS | Kestra Medical Technologies, Ltd. | Stock-Other | 12.49% | +1.51% | -25.59% | |
| 5 | BBNX | Beta Bionics Inc | Stock-Other | 8.08% | +3.03% | — | |
| 6 | ✓ | Engene Holdings Inc | Stock-Other | 3.66% | -2.84% | — | |
| 7 | ALMS | Alumis Inc | Stock-Other | 3.26% | +0.40% | -63.07% | |
| 8 | SANA | Sana Biotechnology Inc | Stock-Other | 1.49% | +0.10% | — | |
| 9 | IMA | Imagenebio Inc | Stock-Other | 1.40% | +0.05% | — | |
| 10 | REPL | Replimune Group Inc | Stock-Other | 1.17% | -1.17% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BCAX | Bicara Therapeutics Inc | +16.2% | +8.50% | Add |
| 2 | BBOT | Bridgebio Oncology Therapeut | +3.7% | — | Unchanged |
| 3 | ALMS | Alumis Inc | +1% | -63.07% | Trim |
| 4 | ✓ | Engene Holdings Inc | +0.9% | — | Unchanged |
| 5 | REPL | Replimune Group Inc | +0.3% | — | Unchanged |
| 6 | IMA | Imagenebio Inc | +0.3% | — | Unchanged |
| 7 | SANA | Sana Biotechnology Inc | +0.3% | — | Unchanged |
| 8 | KMTS | Kestra Medical Technologies, Ltd. | -0.2% | -25.59% | Trim |
| 9 | NUVB | Nuvation Bio Inc | -4% | — | Unchanged |
| 10 | BBNX | Beta Bionics Inc | -5.9% | — | Unchanged |
| 11 | UPB | Upstream Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Omega Fund Management, LLC reported a total U.S. public equity portfolio value of $185.7M across 10 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BCAX, NUVB, BBOT) accounted for 78.2% of total reported equity market value during Q1 2026.
Top Position Liquidated / Trimmed
UPB
前期市值: $36.0M
During Q1 2026, Omega Fund Management, LLC's top holdings by market value included BCAX (29.2%)、NUVB (21.3%)、BBOT (18.1%). The largest single position, BCAX, represented 29.2% of total portfolio value.
In Q1 2026, Omega Fund Management, LLC made 4 total portfolio adjustments, initiating 0 new buys, adding to 1 positions, trimming 2 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.